Tochiya M, Makino H, Tamanaha T, et al. - Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of heart failure in patients with type 2 diabetes, but the mechanisms of action are not well understood, so in 26 patients with type 2 diabetes and heart diseases, researchers conducted this pilot study to assess the impact of tofogliflozin treatment for 6 months on cardiac and vascular endothelial function. Investigators found that left ventricular end-diastolic dimensions were significantly reduced and flow-mediated vasodilation was significantly increased with treatment with tofogliflozin. In patients with type 2 diabetes, SGLT2 inhibitor may improve left ventricular dilatation and vascular endothelial function. In left ventricular diastolic dysfunction, the rise in ketone bodies caused by SGLT2 inhibitors may contribute to a protective impact.